JP2014520068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520068A5 JP2014520068A5 JP2014505323A JP2014505323A JP2014520068A5 JP 2014520068 A5 JP2014520068 A5 JP 2014520068A5 JP 2014505323 A JP2014505323 A JP 2014505323A JP 2014505323 A JP2014505323 A JP 2014505323A JP 2014520068 A5 JP2014520068 A5 JP 2014520068A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adrenergic receptor
- alpha
- nasal
- brimonidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 10
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 5
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 5
- 229960003679 brimonidine Drugs 0.000 claims 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 210000001944 turbinate Anatomy 0.000 claims 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 206010064948 Viral rhinitis Diseases 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 claims 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 claims 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims 1
- 229960002610 apraclonidine Drugs 0.000 claims 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 claims 1
- 229960004253 dexmedetomidine Drugs 0.000 claims 1
- 229960002048 guanfacine Drugs 0.000 claims 1
- 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 claims 1
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 claims 1
- 229960005209 lofexidine Drugs 0.000 claims 1
- -1 mibazelol Chemical compound 0.000 claims 1
- 208000010753 nasal discharge Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/066,370 | 2011-04-13 | ||
| US13/066,370 US20110257188A1 (en) | 2008-08-01 | 2011-04-13 | Compositions and methods for the treatment of nasal conditions |
| US13/406,321 | 2012-02-27 | ||
| US13/406,321 US20120156244A1 (en) | 2008-08-01 | 2012-02-27 | Nasal Compositions and Uses Thereof |
| PCT/US2012/033461 WO2012142372A2 (en) | 2011-04-13 | 2012-04-13 | Compositions and methods for the treatment of nasal conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014520068A JP2014520068A (ja) | 2014-08-21 |
| JP2014520068A5 true JP2014520068A5 (enExample) | 2015-05-28 |
Family
ID=47009984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505323A Withdrawn JP2014520068A (ja) | 2011-04-13 | 2012-04-13 | 鼻の状態の治療のための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120156244A1 (enExample) |
| EP (1) | EP2696874A4 (enExample) |
| JP (1) | JP2014520068A (enExample) |
| CA (1) | CA2832953A1 (enExample) |
| WO (1) | WO2012142372A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| US20150119401A1 (en) * | 2008-08-01 | 2015-04-30 | Eye Therapies, Llc | Compositions and Methods for the Treatment of Nasal Conditions |
| US8445526B2 (en) * | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
| CA2889833A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| RU2016111112A (ru) * | 2013-08-26 | 2017-09-29 | ПиЭс ТЕРЭПИС ЛТД. | Композиции и способы для лечения патологических состояний носа |
| KR101831290B1 (ko) | 2013-10-07 | 2018-02-22 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물 |
| TWI704933B (zh) | 2013-10-07 | 2020-09-21 | 美商帝國製藥美國股份有限公司 | 右美托咪啶經皮輸送裝置及使用其之方法 |
| KR101891185B1 (ko) | 2013-10-07 | 2018-08-24 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물 |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US20170007704A1 (en) * | 2015-07-09 | 2017-01-12 | David Ram | Carrier and pharmaceutical compositions for intrasinal delivery and uses thereof |
| WO2017139382A1 (en) * | 2016-02-08 | 2017-08-17 | The Texas A&M University System | Combination of adjuvant drugs esketamine and brimonidine for medical treatments |
| WO2020065085A1 (fr) * | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Composition pharmaceutique comprenant de la brimonidine, et ses utilisations |
| WO2021222525A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine compositions and methods of use |
| CN117982422B (zh) * | 2024-04-03 | 2024-07-26 | 深圳大佛药业股份有限公司 | 一种用于治疗鼻炎的喷雾剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087361A (en) * | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
| EP0903151A1 (en) * | 1997-09-22 | 1999-03-24 | ASTA Medica Aktiengesellschaft | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms |
| US5948414A (en) * | 1998-03-24 | 1999-09-07 | Nouveau Technologies, Inc. | Herbal based nasal spray |
| US6565832B1 (en) * | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
| WO2002005853A2 (en) * | 2000-07-14 | 2002-01-24 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20030236275A1 (en) * | 2002-06-20 | 2003-12-25 | Schering Corporation | Treatment methods of nasal congestion and nasal obstruction |
| US20070202050A1 (en) * | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
| US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
| US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
| US8283350B2 (en) * | 2008-08-01 | 2012-10-09 | Alpha Synergy Development, Inc. | Compositions and methods for reducing capillary permeability |
-
2012
- 2012-02-27 US US13/406,321 patent/US20120156244A1/en not_active Abandoned
- 2012-04-13 WO PCT/US2012/033461 patent/WO2012142372A2/en not_active Ceased
- 2012-04-13 CA CA2832953A patent/CA2832953A1/en not_active Abandoned
- 2012-04-13 JP JP2014505323A patent/JP2014520068A/ja not_active Withdrawn
- 2012-04-13 EP EP12771888.0A patent/EP2696874A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520068A5 (enExample) | ||
| CA2732521A1 (en) | Vasoconstriction compositions and methods of use | |
| CA2782817A1 (en) | Compositions and methods for eye whitening | |
| MX382748B (es) | Compuestos heterociclicos utiles para el tratamiento de una enfermedad. | |
| JP2013509429A5 (enExample) | ||
| JP2011057670A5 (enExample) | ||
| PE20060257A1 (es) | Composicion farmaceutica de flibanserina para el tratamiento de trastornos premestruales y otros trastornos sexuales femeninos | |
| JP2012500004A5 (enExample) | ||
| JP2014515013A5 (enExample) | ||
| MY152669A (en) | Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid | |
| JP2011516477A5 (enExample) | ||
| JP2008526757A5 (enExample) | ||
| JP2017530983A5 (enExample) | ||
| JP2013518056A5 (enExample) | ||
| JP2013509441A5 (enExample) | ||
| JP2014520068A (ja) | 鼻の状態の治療のための組成物および方法 | |
| PE20081751A1 (es) | Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor | |
| HK1206607A1 (en) | Compounds and methods for treating aberrant adrenocortical cell disorders | |
| RU2013110003A (ru) | Комбинация соединений для лечения или предотвращения кожных заболеваний | |
| JP2011513393A5 (enExample) | ||
| WO2015097600A3 (en) | Topical brimonidine tartrate ophthalmic solution | |
| JP2008540528A5 (enExample) | ||
| JP2011524362A5 (enExample) | ||
| JP2010529142A5 (enExample) | ||
| JP2012520302A5 (enExample) |